Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PGN-EDO51 in Duchenne Muscular Dystrophy amenable to exon 51-skipping
NCT06079736Phase 2Terminated
- Sponsor
- PepGen
- Start
- Jan 2024
- Primary completion
- Aug 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of PGN-EDO51 in Duchenne muscular dystrophy (DMD), sponsored by PepGen. Started Jan 2024; status: terminated.
02
Drugs
PGN-EDO51
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06079736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079736.